Oxford BioMedica plc (OXB.L)
Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates various therapeutic genes. The company's products include Axo-Lenti-PD, a gene-based treatment for parkinson's disease; OXB-302, which is in pre-clinical stage for the treatment of haematological malignancies and tumours; and OXB-401 that is in pre-clinical stage for the treatment of liver indication; as well as OXB-40X, OXB-40Y, and OXB-40Z, which are in pre-clinical stage for liver indication. The company has collaborations with Boehringer Ingelheim, Immatics, Arcellx, Orchard, and Beam Therapeutics; an agreement with Homology Medicines; license and clinical supply agreement with Juno Therapeutics, Inc.; and master services and development agreement with AstraZeneca UK Ltd and Serum Life Sciences Ltd. The company also has a strategic collaboration with Kite Pharma to develop and commercialize CART-ddBCMA, a lead late-stage product candidate. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.
Company Info
Highlights
£406.91M
-£1.44
£50.81M
£17.96M
-£19.67M
£167.00 - £455.00
£530.25
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of £10,000 in Oxford BioMedica plc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Oxford BioMedica plc had a return of -9.05% year-to-date (YTD) and 126.04% in the last 12 months. Over the past 10 years, Oxford BioMedica plc had an annualized return of -1.00%, while the S&P 500 had an annualized return of 11.31%, indicating that Oxford BioMedica plc did not perform as well as the benchmark.
OXB.L
-9.05%
-5.68%
8.99%
126.04%
-11.02%
-1.00%
^GSPC (Benchmark)
4.46%
2.46%
9.31%
23.49%
13.03%
11.31%
Monthly Returns
The table below presents the monthly returns of OXB.L, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -0.71% | -9.05% | |||||||||||
| 2024 | -17.36% | -5.39% | 16.86% | 37.56% | 19.71% | -10.42% | 24.79% | -9.46% | 12.09% | 5.99% | 7.66% | -1.98% | 90.91% |
| 2023 | -3.73% | 29.11% | -21.00% | -0.12% | 3.34% | -6.35% | 5.24% | -27.04% | -5.27% | -30.61% | -21.32% | 31.89% | -50.28% |
| 2022 | -31.38% | -11.37% | -9.89% | -15.43% | -10.35% | -11.15% | 6.39% | -5.38% | -24.18% | -6.64% | 17.31% | 16.60% | -64.02% |
| 2021 | -4.76% | 3.16% | -5.93% | 14.71% | 4.40% | 14.04% | 2.46% | 11.26% | 4.45% | -1.68% | -13.40% | -6.68% | 19.42% |
| 2020 | -6.20% | 4.30% | -14.58% | 35.44% | 5.62% | -9.08% | 16.55% | 3.30% | -2.84% | -1.95% | 7.59% | 19.08% | 59.69% |
| 2019 | -2.43% | -2.97% | 6.50% | -1.96% | 6.44% | -7.12% | -0.14% | -9.57% | -13.46% | 3.33% | 11.65% | 3.53% | -8.80% |
| 2018 | 22.71% | 11.42% | -8.60% | 8.68% | 10.10% | 49.00% | -9.73% | -1.42% | 4.22% | -24.53% | 2.41% | 0.07% | 59.82% |
| 2017 | 3.69% | -4.98% | 28.93% | -14.12% | 12.61% | 49.00% | 15.44% | 14.65% | -5.07% | -4.38% | 0.56% | -1.67% | 117.44% |
| 2016 | 8.15% | -6.26% | -12.90% | -0.70% | -5.09% | -13.12% | -9.79% | -0.94% | -21.43% | 20.61% | -11.06% | 14.97% | -37.38% |
| 2015 | 33.33% | 13.57% | 54.09% | -8.16% | -11.56% | -8.04% | 0.98% | -11.80% | -0.86% | -22.03% | -3.17% | 6.56% | 23.81% |
| 2014 | 40.86% | -6.11% | -19.51% | -10.10% | -7.87% | 36.59% | 4.46% | 20.51% | 5.67% | 8.05% | 22.36% | 6.60% | 125.81% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
With an overall rank of 94, OXB.L is among the top 6% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Oxford BioMedica plc (OXB.L) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the Oxford BioMedica plc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Oxford BioMedica plc was 98.73%, occurring on Jul 22, 2013. The portfolio has not yet recovered.
The current Oxford BioMedica plc drawdown is 92.70%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -98.73% | Feb 24, 2000 | 3372 | Jul 22, 2013 | — | — | — |
| -88.12% | Dec 30, 1996 | 349 | Oct 20, 1998 | 194 | Jan 17, 2000 | 543 |
| -26.9% | Jan 24, 2000 | 11 | Feb 8, 2000 | 5 | Feb 16, 2000 | 16 |
| -9.09% | Feb 21, 2000 | 1 | Feb 21, 2000 | 1 | Feb 22, 2000 | 2 |
| -6.37% | Jan 18, 2000 | 1 | Jan 18, 2000 | 2 | Jan 20, 2000 | 3 |
Volatility
Volatility Chart
The current Oxford BioMedica plc volatility is 9.70%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
Historical P/E Ratio Chart
The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Oxford BioMedica plc.
Loading data...
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |